Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma
Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.
Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab (Tecentriq) as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.
In the phase II study, 119 patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months following treatment with atezolizumab.
During the trial, atezolizumab was administered at 1200 mg every 3 weeks until progression. The objective response rate was 24%; additionally, 75% of these responses are still ongoing. The complete response rate was 7%, while the partial response rate was 17%.
<<<
